pubmed-article:21284407 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:21284407 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
pubmed-article:21284407 | lifeskim:mentions | umls-concept:C0750848 | lld:lifeskim |
pubmed-article:21284407 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
pubmed-article:21284407 | lifeskim:mentions | umls-concept:C0406317 | lld:lifeskim |
pubmed-article:21284407 | lifeskim:mentions | umls-concept:C0282461 | lld:lifeskim |
pubmed-article:21284407 | lifeskim:mentions | umls-concept:C0460977 | lld:lifeskim |
pubmed-article:21284407 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
pubmed-article:21284407 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:21284407 | pubmed:dateCreated | 2011-4-7 | lld:pubmed |
pubmed-article:21284407 | pubmed:abstractText | Corticosteroids are a versatile option for the treatment of mild-to-moderate psoriasis due to their availability in a wide range of potencies and formulations. Occlusion of the corticosteroid is a widely accepted procedure to enhance the penetration of the medication, thereby improving its effectiveness. Betamethasone valerate (BMV) is a moderately potent corticosteroid that is available as a cream, ointment, and lotion. A ready-to-use occlusive dressing, which provides a continuous sustained release of BMV, has been developed for the treatment of psoriasis. | lld:pubmed |
pubmed-article:21284407 | pubmed:language | eng | lld:pubmed |
pubmed-article:21284407 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21284407 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:21284407 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21284407 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21284407 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:21284407 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:21284407 | pubmed:month | Jun | lld:pubmed |
pubmed-article:21284407 | pubmed:issn | 1175-0561 | lld:pubmed |
pubmed-article:21284407 | pubmed:author | pubmed-author:NaldiLuigiL | lld:pubmed |
pubmed-article:21284407 | pubmed:author | pubmed-author:OrtonneJean-P... | lld:pubmed |
pubmed-article:21284407 | pubmed:author | pubmed-author:YawalkarNikhi... | lld:pubmed |
pubmed-article:21284407 | pubmed:author | pubmed-author:KaszubaAndrze... | lld:pubmed |
pubmed-article:21284407 | pubmed:author | pubmed-author:MorelliPaoloP | lld:pubmed |
pubmed-article:21284407 | pubmed:author | pubmed-author:RovatiStefano... | lld:pubmed |
pubmed-article:21284407 | pubmed:author | pubmed-author:MautoneGiusep... | lld:pubmed |
pubmed-article:21284407 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:21284407 | pubmed:day | 1 | lld:pubmed |
pubmed-article:21284407 | pubmed:volume | 12 | lld:pubmed |
pubmed-article:21284407 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:21284407 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:21284407 | pubmed:pagination | 191-201 | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:meshHeading | pubmed-meshheading:21284407... | lld:pubmed |
pubmed-article:21284407 | pubmed:year | 2011 | lld:pubmed |
pubmed-article:21284407 | pubmed:articleTitle | Efficacy and safety of the Betamethasone valerate 0.1% plaster in mild-to-moderate chronic plaque psoriasis: a randomized, parallel-group, active-controlled, phase III study. | lld:pubmed |
pubmed-article:21284407 | pubmed:affiliation | Clinica Dermatologica, Ospedali Riuniti, Centro Studi GISED, Bergamo, Italy. | lld:pubmed |
pubmed-article:21284407 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:21284407 | pubmed:publicationType | Comparative Study | lld:pubmed |
pubmed-article:21284407 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:21284407 | pubmed:publicationType | Multicenter Study | lld:pubmed |
pubmed-article:21284407 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |